Mobosetinib (mobosetinib) is an introduction to several generations of targeted drugs

Mobocertinib (Mobocertinib) is a targeted drug used to treat non-small cell lung cancer (NSCLC) and is a "third generation" targeted drug. It is mainly used to treat lung cancer caused by epidermal growth factor receptor (EGFR) mutations, especially when patients with lung cancer caused by EGFR mutations are resistant to other treatments. The mechanism of action of Mobotinib is different from traditional targeted drugs. It is characterized by its ability to effectively target tumors with EGFR exon 20 mutations, especially for lung cancer patients carrying EGFR T790M mutations.

Targeted drugs can be divided into first-, second- and third-generation drugs based on the types of mutations they target. The first generation of targeted drugs (such as gefitinib and erlotinib) mainly target common mutations of EGFR, but have limited effect on some special EGFR mutations (such as exon 20 insertion mutations). Second-generation targeted drugs (such as afatinib) prevent tumor growth by inhibiting the activation of EGFR, but their effectiveness against drug-resistant mutations is still lacking. The third generation of targeted drugs are optimized for these drug-resistant mutations and can effectively deal with lung cancer related to EGFR mutations, including tumors with T790M and exon 20 insertion mutations.

Mobotinib, as a third-generation targeted drug, has high specificity and selectivity. It irreversibly inhibits the kinase activity of EGFR mutants, especially those EGFR exon 20 insertion mutations that cannot be effectively inhibited by traditional drugs. Mobotinib inhibits the kinase activity of the receptor by binding to the ATP binding site of the EGFR receptor, thereby preventing the proliferation and growth of tumor cells. Compared with other second-generation drugs, mobotinib has obvious advantages in combating resistance caused by EGFR mutations.

Clinical studies of mobotinib have shown that for patients carrying EGFR exon20In patients with advanced non-small cell lung cancer with insertional mutations, mobotinib has significant advantages in efficacy. In clinical trials, mobotinib was able to significantly extend patients' progression-free survival (PFS) and had a high objective response rate (ORR). Especially in patients who are resistant to other EGFR targeted drugs, mobotinib has shown a good therapeutic effect, making it a first-line option for the treatment of this type of specially mutated non-small cell lung cancer.

References：https://en.wikipedia.org/wiki/Mobocertinib